Clinical Trials Browser

Neoplasms, Nerve Tissue, Neurofibromatosis 1, Peripheral Nervous System Diseases, Neurofibroma, Plexiform, Heredodegenerative Disorders, Nervous System

NCT01479582 2018-12-21

Providing Access to Cord Blood Units for Transplants

Phase 2 Withdrawn

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Non-Hodgkin, Multiple Myeloma, Thalassemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Lysosomal Storage Diseases, Hematologic Neoplasms

NCT03220009 2018-10-03

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

Phase 2 Withdrawn

DermatologicGastrointestinalGynecologic

Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Vaginal Neoplasms, Vulvar Neoplasms

NCT03377101 2018-08-14

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

Phase 2 Withdrawn

Breast

Estrogen Receptor Positive

NCT01251172 2017-09-28

RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 2 Withdrawn

Plasma cell

Multiple Myeloma

NCT01095523 2017-07-02

Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases

Phase 2 Withdrawn

GastrointestinalGynecologic

Colonic Neoplasms, Neoplasm Metastasis, Peritoneal Neoplasms, Rectal Neoplasms, Recurrence, Colorectal Neoplasms

NCT01413438 2017-07-02

Bevacizumab With or Without Surgery for Adult Glioblastomas

Phase 2 Withdrawn

CNS

Brain Neoplasms, Glioblastoma

NCT01270438 2017-04-04

Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT01271283 2015-06-04

Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01851408 2015-04-15

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Phase 2 Withdrawn

Dermatologic

Melanoma, Recurrence

NCT01859182 2014-09-09

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

Phase 2 Withdrawn

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular

NCT01105390 2013-08-02

AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

Phase 2 Withdrawn

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT00003455 2013-07-10

Antineoplaston Therapy in Treating Women With Advanced Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT00003486 2013-07-10

Antineoplaston Therapy in Treating Patients With Colon Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms

NCT00003502 2013-07-10

Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma

Phase 2 Withdrawn

Lymphoid

Lymphoma, Mantle-Cell

NCT00003517 2013-07-10

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT00040989 2013-07-10

BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer

Phase 2 Withdrawn

Genitourinary

Carcinoma, Renal Cell

NCT00080613 2013-07-10

Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer

Phase 2 Withdrawn

Breast

Breast Neoplasms

NCT00112879 2013-07-10

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

Phase 2 Withdrawn

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00389766 2013-07-10

High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma

Phase 2 Withdrawn

CNS

Neuroblastoma

NCT00025051 2013-03-22

Celecoxib in Preventing Skin Cancer

Phase 2 Withdrawn

Dermatologic

Carcinoma, Basal Cell

NCT01216787 2013-01-31

RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery

Phase 2 Withdrawn

Dermatologic

Melanoma

Clinical Trials

Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma

Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial

CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies

Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

Oral Iloprost for the Prevention of Lung Cancer In Former Smokers

Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)

Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)

N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer

Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial

Non-Viral TCR Gene Therapy

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab

A Phase II Study of Neoadjuvant E7 TCR T Cell Immunotherapy for Borderline Resectable and Unresectable Stage I HPV-Associated Oropharyngeal Cancer

Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)

Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral

Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma

Imaging Studies and the Development of Multiple Myeloma

MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma

Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance

18F-CP18 Imaging Studies for Cancer Treatment With Birinapant

Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)

Providing Access to Cord Blood Units for Transplants

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases

Bevacizumab With or Without Surgery for Adult Glioblastomas

Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer

Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

Antineoplaston Therapy in Treating Women With Advanced Breast Cancer

Antineoplaston Therapy in Treating Patients With Colon Cancer

Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma

Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer

BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer

Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma

Celecoxib in Preventing Skin Cancer

RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery